{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:35:00Z","timestamp":1786746900212,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To observe the clinical features and efficacy of immunosuppressive therapy in patients with primary Sj\u00f6gren's syndrome (PSS) combined with peripheral neuropathy (PN) syndrome and to explore the risk factors for PN in patients with PSS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Sixty consecutive patients with PSS admitted to the Department of Rheumatology and Immunology, Wuhan No. 1 Hospital, from January 2014 to June 2020 were analysed retrospectively. Patients were divided into a PN group (<jats:italic>N<\/jats:italic>\u2009=\u200915) and a non-PN group (<jats:italic>N<\/jats:italic>\u2009=\u200945). The clinical characteristics of the two groups were compared, and the independent risk factors for PN combined with PSS were analysed by multivariate logistic regression. The patients with PSS combined with PN were followed up to observe the effect of immunosuppressive therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patients with PN had a longer course of disease than those without PN (<jats:italic>z<\/jats:italic>\u2009=\u2009\u2212\u20093.225, <jats:italic>P<\/jats:italic>\u2009=\u20090.001), and the incidence of Raynaud's phenomenon, anti-SSB antibody, rheumatoid factor and hyperglobulinaemia was higher (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) in patients with PN than in those without PN. Multivariate logistic regression analysis showed that hyperglobulinaemia, RF and anti-SSB antibodies were independent risk factors for PN with PSS (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Fourteen patients with PSS-PN were treated with immunosuppressants. The clinical symptoms of 10 patients were relieved, and mRS scores of 10 patients were decreased.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PN is a common complication in PSS patients. Patients with PSS combined with PN have a longer course of disease and a significantly higher percentage of Raynaud's phenomenon, positive anti-SSB antibody, positive RF and hyperglobulinaemia. Immunosuppressive therapy was effective for partial remission of PN with PSS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-023-01013-w","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T05:03:27Z","timestamp":1675055007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Analysis of clinical features and risk factors of peripheral neuropathy in patients with primary Sj\u00f6gren's syndrome"],"prefix":"10.1186","volume":"28","author":[{"given":"Zhihong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaipu","family":"Xianyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"issue":"11","key":"1013_CR1","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","volume":"74","author":"B Qin","year":"2015","unstructured":"Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjogren\u2019s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1013_CR2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/jnnp.2010.222109","volume":"82","author":"PP Pavlakis","year":"2011","unstructured":"Pavlakis PP, Alexopoulos H, Kosmidis ML, Stamboulis E, Routsias JG, Tzartos SJ, et al. Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry. 2011;82(7):798\u2013802.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1013_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s004150170135","volume":"248","author":"C Lafitte","year":"2001","unstructured":"Lafitte C, Amoura Z, Cacoub P, Pradat-Diehl P, Picq C, Salachas F, et al. Neurological complications of primary Sjogren\u2019s syndrome. J Neurol. 2001;248(7):577\u201384.","journal-title":"J Neurol"},{"issue":"Pt 11","key":"1013_CR4","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1093\/brain\/awh605","volume":"128","author":"K Mori","year":"2005","unstructured":"Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjogren\u2019s syndrome-associated neuropathy. Brain. 2005;128(Pt 11):2518\u201334.","journal-title":"Brain"},{"issue":"1","key":"1013_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jns.12298","volume":"24","author":"M Sopacua","year":"2019","unstructured":"Sopacua M, Hoeijmakers JGJ, Merkies ISJ, Lauria G, Waxman SG, Faber CG. Small-fiber neuropathy: expanding the clinical pain universe. J Peripher Nerv Syst. 2019;24(1):19\u201333.","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"1013_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/ard.62.1.94","volume":"62","author":"C Vitali","year":"2003","unstructured":"Vitali C. Classification criteria for Sjogren\u2019s syndrome. Ann Rheum Dis. 2003;62(1):94\u20135 (author reply 5).","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1013_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/acr.21591","volume":"64","author":"SC Shiboski","year":"2012","unstructured":"Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjogren\u2019s syndrome: a data-driven, expert consensus approach in the Sjogren\u2019s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64(4):475\u201387.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"1013_CR8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/mus.25204","volume":"54","author":"T Dillingham","year":"2016","unstructured":"Dillingham T, Chen S, Andary M, Buschbacher R, Del Toro D, Smith B, et al. Establishing high-quality reference values for nerve conduction studies: a report from the normative data task force of the American Association of Neuromuscular & Electrodiagnostic Medicine. Muscle Nerve. 2016;54(3):366\u201370.","journal-title":"Muscle Nerve"},{"issue":"7","key":"1013_CR9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.clinph.2005.04.003","volume":"116","author":"H Tankisi","year":"2005","unstructured":"Tankisi H, Pugdahl K, Fuglsang-Frederiksen A, Johnsen B, de Carvalho M, Fawcett PR, et al. Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines. Clin Neurophysiol. 2005;116(7):1571\u201380.","journal-title":"Clin Neurophysiol"},{"issue":"6","key":"1013_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/ard.2009.110619","volume":"69","author":"R Seror","year":"2010","unstructured":"Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren\u2019s syndrome. Ann Rheum Dis. 2010;69(6):1103\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1013_CR11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.rdc.2008.08.002","volume":"34","author":"C Vitali","year":"2008","unstructured":"Vitali C. Measurement of disease activity and damage in Sjogren\u2019s syndrome. Rheum Dis Clin North Am. 2008;34(4):963\u201371.","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"1013_CR12","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00296-020-04543-2","volume":"40","author":"M Jaskolska","year":"2020","unstructured":"Jaskolska M, Chylinska M, Masiak A, Nowicka-Sauer K, Sieminski M, Zietkiewicz M, et al. Peripheral neuropathy and health-related quality of life in patients with primary Sjogren\u2019s syndrome: a preliminary report. Rheumatol Int. 2020;40(8):1267\u201374.","journal-title":"Rheumatol Int"},{"issue":"8","key":"1013_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1665","volume":"10","author":"M Jaskolska","year":"2020","unstructured":"Jaskolska M, Chylinska M, Masiak A, Sieminski M, Zietkiewicz M, Czuszynska Z, et al. Neuro-Sjogren: uncommon or underestimated problem? Brain Behav. 2020;10(8): e01665.","journal-title":"Brain Behav"},{"issue":"8","key":"1013_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/jnnp.57.8.983","volume":"57","author":"F Gemignani","year":"1994","unstructured":"Gemignani F, Marbini A, Pavesi G, Di Vittorio S, Manganelli P, Cenacchi G, Mancia D. Peripheral neuropathy associated with primary. J Neurol Neurosurg Psychiatry. 1994;57(8):983\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1013_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/ene.15555","volume":"30","author":"A Liampas","year":"2023","unstructured":"Liampas A, Parperis K, Erotocritou MF, Nteveros A, Papadopoulou M, Moschovos C, et al. Primary Sjogren syndrome-related peripheral neuropathy: a systematic review and meta-analysis. Eur J Neurol. 2023;30(1):255\u201365.","journal-title":"Eur J Neurol"},{"issue":"7","key":"1013_CR16","first-page":"1552","volume":"30","author":"J Font","year":"2003","unstructured":"Font J, Ramos-Casals M, de la Red G, Pou A, Casanova A, Garcia-Carrasco M, et al. Pure sensory neuropathy in primary Sjogren\u2019s syndrome. Long term prospective follow up and review of the literature. J Rheumatol. 2003;30(7):1552\u20137.","journal-title":"J Rheumatol"},{"issue":"5","key":"1013_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/acn3.51053","volume":"7","author":"J Tani","year":"2020","unstructured":"Tani J, Liao HT, Hsu HC, Chen LF, Chang TS, Shin-Yi Lin C, et al. Immune-mediated axonal dysfunction in seropositive and seronegative primary Sjogren\u2019s syndrome. Ann Clin Transl Neurol. 2020;7(5):819\u201328.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"1013_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MD.0b013e31820fd2d1","volume":"90","author":"D Sene","year":"2011","unstructured":"Sene D, Jallouli M, Lefaucheur JP, Saadoun D, Costedoat-Chalumeau N, Maisonobe T, et al. Peripheral neuropathies associated with primary Sjogren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine. 2011;90(2):133\u20138.","journal-title":"Medicine"},{"issue":"5","key":"1013_CR19","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1097\/MD.0000000000000005","volume":"92","author":"D Sene","year":"2013","unstructured":"Sene D, Cacoub P, Authier FJ, Haroche J, Creange A, Saadoun D, et al. Sjogren syndrome-associated small fiber neuropathy: characterization from a prospective series of 40 cases. Medicine. 2013;92(5):e10\u20138.","journal-title":"Medicine"},{"key":"1013_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/902492","volume":"2014","author":"CW Hsu","year":"2014","unstructured":"Hsu CW, Su YJ, Chang WN, Tsai NW, Chiu WC, Cheng BC, et al. The association between serological biomarkers and primary Sjogren\u2019s syndrome associated with peripheral polyneuropathy. Biomed Res Int. 2014;2014: 902492.","journal-title":"Biomed Res Int"},{"issue":"2","key":"1013_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ejim.2013.10.005","volume":"25","author":"Y Jamilloux","year":"2014","unstructured":"Jamilloux Y, Magy L, Hurtevent JF, Gondran G, de Seze J, Launay D, et al. Immunological profiles determine neurological involvement in Sjogren\u2019s syndrome. Eur J Intern Med. 2014;25(2):177\u201381.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"1013_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12868-018-0427-y","volume":"19","author":"W Ye","year":"2018","unstructured":"Ye W, Chen S, Huang X, Qin W, Zhang T, Zhu X, et al. Clinical features and risk factors of neurological involvement in Sjogren\u2019s syndrome. BMC Neurosci. 2018;19(1):26.","journal-title":"BMC Neurosci"},{"key":"1013_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.615656","volume":"12","author":"G Cafaro","year":"2021","unstructured":"Cafaro G, Perricone C, Carubbi F, Baldini C, Quartuccio L, Priori R, et al. Peripheral nervous system involvement in Sjogren\u2019s syndrome: analysis of a cohort from the Italian research group on Sjogren\u2019s syndrome. Front Immunol. 2021;12: 615656.","journal-title":"Front Immunol"},{"issue":"1","key":"1013_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brito-Zeron P, Bombardieri S, Bootsma H, De Vita S, Dorner T, et al. EULAR recommendations for the management of Sjogren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1013_CR25","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1007\/s00415-020-10033-z","volume":"267","author":"T Pindi Sala","year":"2020","unstructured":"Pindi Sala T, Villedieu M, Damian L, Crave JC, Pautot V, Stojanovich L, et al. Long-term efficacy of immunoglobulins in small fiber neuropathy related to Sjogren\u2019s syndrome. J Neurol. 2020;267(12):3499\u2013507.","journal-title":"J Neurol"},{"issue":"1","key":"1013_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","volume":"71","author":"A Mekinian","year":"2012","unstructured":"Mekinian A, Ravaud P, Hatron PY, Larroche C, Leone J, Gombert B, et al. Efficacy of rituximab in primary Sjogren\u2019s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71(1):84\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1013_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clnesp.2022.05.015","volume":"50","author":"S Hirsch","year":"2022","unstructured":"Hirsch S, Skripuletz T, Seeliger T, Witte T, Thiele T. Selenium deficiency is associated with polyneuropathy in primary Sjogren\u2019s syndrome. Clin Nutr ESPEN. 2022;50:212\u20137.","journal-title":"Clin Nutr ESPEN"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01013-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01013-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01013-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T05:09:55Z","timestamp":1675055395000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01013-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01013-w","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the No. 1 Hospital of Wuhan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that there are no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}